Physician profile
Jason Baynes
NPI 1720279243
$12,956.69
in general payments reported to CMS, 2019-2025
14 companies · $628 in 2025
The $628 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,813 · 2020: $362 · 2021: $1,968 · 2022: $721 · 2023: $1,058 · 2024: $2,407 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261 · Travel and Lodging: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.36 |
| Travel and Lodging | $1,831.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $5,515.70 | 2019-2024 | |
| Seapearl East, INC | $4,479.29 | 2019-2024 | |
| Fidia Pharma USA INC. | $688.23 | 2019-2023 | Hymovis, Triluron |
| Horizon Therapeutics Plc | $469.44 | 2019-2023 | Krystexxa |
| Kerecis Limited | $358.04 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Stratus Medical, LLC | $285.15 | 2023 | Nimbus |
| Boston Scientific Corporation | $231.09 | 2021-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Zimmer Biomet Holdings, INC. | $183.81 | 2021-2025 | Persona |
| Lima USA, INC. | $149.68 | 2019 | |
| Orthofix Medical, INC. | $137.10 | 2023 | Spinal-Stim, Spinal-Stim |
| Royal Biologics, INC. | $125.41 | 2019 | |
| Integra Lifesciences Corporation | $120.23 | 2019 | |
| Heron Therapeutics, INC. | $118.55 | 2025 | Zynrelef |
| Si-Bone, INC. | $94.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Baynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.